4105.TWO
Price:
$75.1
Market Cap:
$18.67B
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin,...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2007-12-31
Stock Exchange
TWO
Ticker
4105.TWO
According to TTY Biopharm Company Limited’s latest financial reports and current stock price. The company's current PE Ratio is 12.00. This represents a change of -5.04% compared to the average of 12.64 of the last 4 quarters.
The mean historical PE Ratio of TTY Biopharm Company Limited over the last ten years is 18.50. The current 12.00 PE Ratio has changed 6.39% with respect to the historical average. Over the past ten years (40 quarters), 4105.TWO's PE Ratio was at its highest in in the December 2023 quarter at 24.46. The PE Ratio was at its lowest in in the December 2024 quarter at 8.47.
Average
18.50
Median
18.70
Minimum
12.49
Maximum
22.76
Discovering the peaks and valleys of TTY Biopharm Company Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 11.42%
Maximum Annual PE Ratio = 22.76
Minimum Annual Increase = -29.69%
Minimum Annual PE Ratio = 12.49
Year | PE Ratio | Change |
---|---|---|
2024 | 12.49 | -29.69% |
2023 | 17.76 | -6.28% |
2022 | 18.95 | -7.85% |
2021 | 20.56 | 11.42% |
2020 | 18.46 | -18.92% |
The current PE Ratio of TTY Biopharm Company Limited (4105.TWO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
16.40
5-year avg
17.64
10-year avg
18.50
TTY Biopharm Company Limited’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TTY Biopharm Company Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TTY Biopharm Company Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is TTY Biopharm Company Limited's PE Ratio?
How is the PE Ratio calculated for TTY Biopharm Company Limited (4105.TWO)?
What is the highest PE Ratio for TTY Biopharm Company Limited (4105.TWO)?
What is the 3-year average PE Ratio for TTY Biopharm Company Limited (4105.TWO)?
What is the 5-year average PE Ratio for TTY Biopharm Company Limited (4105.TWO)?
How does the current PE Ratio for TTY Biopharm Company Limited (4105.TWO) compare to its historical average?